LOGIN  |  REGISTER
Terns Pharmaceuticals
Astria Therapeutics

Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1

October 16, 2023 | Last Trade: US$15.67 0.08 -0.51

VAUGHAN, Ontario / Oct 16, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2023 financial results on Wednesday, Nov. 1, 2023. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

Conference Call Details

Date:

 

Wednesday, Nov. 1, 2023

   

Time:

 

8 a.m. ET

   

Webcast:

 

https://www.webcaster4.com/Webcast/Page/2883/47447

   

Participant Event Dial-in:

 

+1 (888) 506-0062 (North America)

+1 (973) 528-0011 (International)

   

Participant Access Code:

 

632888

   

Replay Dial-in:

 

+1 (877) 481-4010 (North America)

+1 (919) 882-2331 (International)

   

Replay Passcode:

 

47447 (replay available until Nov. 15, 2023)

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.

Astria Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page